[{"id":"9272430e-eab6-4fc0-8844-69d711337ecc","acronym":"ENDURE","url":"https://clinicaltrials.gov/study/NCT04892953","created_at":"2021-05-19T15:52:50.047Z","updated_at":"2025-02-25T13:40:30.743Z","phase":"Phase 2","brief_title":"Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy","source_id_and_acronym":"NCT04892953 - ENDURE","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" EGFR • ALK • MET • RET • ROS1","pipe":" | ","alterations":" RET fusion • ALK rearrangement • MET exon 14 mutation • ALK fusion • ROS1 fusion • ROS1 rearrangement • RET rearrangement","tags":["EGFR • ALK • MET • RET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion • ALK rearrangement • MET exon 14 mutation • ALK fusion • ROS1 fusion • ROS1 rearrangement • RET rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Imfinzi (durvalumab) • gemcitabine • albumin-bound paclitaxel • pemetrexed • Pemfexy (pemetrexed)"],"overall_status":"Recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 07/07/2021","start_date":" 07/07/2021","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2025-02-21"},{"id":"d9249df0-7324-4379-b412-dbfbc6b5d9e8","acronym":"NAUTIKA1","url":"https://clinicaltrials.gov/study/NCT04302025","created_at":"2021-01-18T20:51:55.005Z","updated_at":"2025-02-25T13:40:05.730Z","phase":"Phase 2","brief_title":"A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT04302025 - NAUTIKA1","lead_sponsor":"Genentech, Inc.","biomarkers":" PD-L1 • KRAS • BRAF • ALK • RET • ROS1 • NTRK1 • NTRK3 • NTRK2","pipe":" | ","alterations":" PD-L1 expression • KRAS mutation • KRAS G12C • BRAF mutation • BRAF V600 • RET fusion • ALK fusion • RET mutation • ROS1 fusion • KRAS G12","tags":["PD-L1 • KRAS • BRAF • ALK • RET • ROS1 • NTRK1 • NTRK3 • NTRK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • KRAS mutation • KRAS G12C • BRAF mutation • BRAF V600 • RET fusion • ALK fusion • RET mutation • ROS1 fusion • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • Rozlytrek (entrectinib) • Alecensa (alectinib) • Cotellic (cobimetinib) • Gavreto (pralsetinib) • divarasib (RG6330)"],"overall_status":"Recruiting","enrollment":" Enrollment 125","initiation":"Initiation: 11/06/2020","start_date":" 11/06/2020","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 03/06/2029","study_completion_date":" 03/06/2029","last_update_posted":"2025-02-21"},{"id":"6fa58343-5f41-4e65-b9b7-ed2e1d17361f","acronym":"LUNG-MAP SUB-STUDY","url":"https://clinicaltrials.gov/study/NCT06116682","created_at":"2023-11-03T20:12:32.614Z","updated_at":"2025-02-25T14:10:16.796Z","phase":"Phase 2","brief_title":"Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)","source_id_and_acronym":"NCT06116682 - LUNG-MAP SUB-STUDY","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" EGFR • HER-2 • KRAS • BRAF • ALK • MET • RET • ROS1 • NTRK","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • HER-2 mutation • MET amplification • EGFR T790M • MET exon 14 mutation • ALK fusion • ROS1 fusion • RET rearrangement","tags":["EGFR • HER-2 • KRAS • BRAF • ALK • MET • RET • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • HER-2 mutation • MET amplification • EGFR T790M • MET exon 14 mutation • ALK fusion • ROS1 fusion • RET rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rybrevant (amivantamab-vmjw) • Rybrevant Faspro (amivantamab and hyaluronidase-lpuj)"],"overall_status":"Recruiting","enrollment":" Enrollment 88","initiation":"Initiation: 11/19/2024","start_date":" 11/19/2024","primary_txt":" Primary completion: 05/31/2028","primary_completion_date":" 05/31/2028","study_txt":" Completion: 05/31/2028","study_completion_date":" 05/31/2028","last_update_posted":"2025-02-19"},{"id":"c3e9ec33-9883-4e28-b473-f95df1486329","acronym":"Lung-Map Screening Study","url":"https://clinicaltrials.gov/study/NCT03851445","created_at":"2021-01-18T19:00:27.801Z","updated_at":"2025-02-25T14:07:20.756Z","phase":"Phase 2/3","brief_title":"Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT03851445 - Lung-Map Screening Study","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" EGFR • BRAF • ALK • MET • ROS1","pipe":" | ","alterations":" BRAF V600E • EGFR mutation • BRAF V600 • EGFR T790M • ALK fusion • ROS1 fusion","tags":["EGFR • BRAF • ALK • MET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • EGFR mutation • BRAF V600 • EGFR T790M • ALK fusion • ROS1 fusion"],"overall_status":"Recruiting","enrollment":" Enrollment 10000","initiation":"Initiation: 02/06/2019","start_date":" 02/06/2019","primary_txt":" Primary completion: 01/28/2029","primary_completion_date":" 01/28/2029","study_txt":" Completion: 01/28/2029","study_completion_date":" 01/28/2029","last_update_posted":"2025-02-17"},{"id":"fc32aaa3-7f5b-404e-9923-86b9a8cde5d8","acronym":"LUNG-MAP SUB-STUDY","url":"https://clinicaltrials.gov/study/NCT06031688","created_at":"2023-09-11T16:10:36.199Z","updated_at":"2025-02-25T14:10:03.191Z","phase":"Phase 2","brief_title":"Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)","source_id_and_acronym":"NCT06031688 - LUNG-MAP SUB-STUDY","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" EGFR • HER-2 • KRAS • BRAF • ALK • MET • RET • ROS1 • NTRK","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • HER-2 mutation • EGFR T790M • MET exon 14 mutation • ALK fusion • ROS1 fusion • RET rearrangement","tags":["EGFR • HER-2 • KRAS • BRAF • ALK • MET • RET • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • HER-2 mutation • EGFR T790M • MET exon 14 mutation • ALK fusion • ROS1 fusion • RET rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cyramza (ramucirumab) • Tepmetko (tepotinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 08/08/2024","start_date":" 08/08/2024","primary_txt":" Primary completion: 05/31/2028","primary_completion_date":" 05/31/2028","study_txt":" Completion: 05/31/2029","study_completion_date":" 05/31/2029","last_update_posted":"2025-02-17"},{"id":"a1cc20b7-e120-4c96-ad2e-1583010cd20c","acronym":"CARE study","url":"https://clinicaltrials.gov/study/NCT04094610","created_at":"2021-01-18T20:02:04.781Z","updated_at":"2025-02-25T14:40:19.057Z","phase":"Phase 1/2","brief_title":"A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations","source_id_and_acronym":"NCT04094610 - CARE study","lead_sponsor":"Turning Point Therapeutics, Inc.","biomarkers":" ALK • ROS1 • NTRK1 • NTRK3 • NTRK2 • NTRK","pipe":" | ","alterations":" ALK fusion • ROS1 fusion • NTRK positive • NTRK fusion","tags":["ALK • ROS1 • NTRK1 • NTRK3 • NTRK2 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK fusion • ROS1 fusion • NTRK positive • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Augtyro (repotrectinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 03/12/2020","start_date":" 03/12/2020","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2025-02-14"},{"id":"6443d84d-18f2-435e-a44c-d58932c7c829","acronym":"SKB264-II-04","url":"https://clinicaltrials.gov/study/NCT05816252","created_at":"2023-04-18T15:04:37.057Z","updated_at":"2025-02-25T15:20:25.216Z","phase":"Phase 2","brief_title":"A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT05816252 - SKB264-II-04","lead_sponsor":"Klus Pharma Inc.","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR mutation • ALK fusion","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Tagrisso (osimertinib) • carboplatin • Jiataile (sacituzumab tirumotecan)"],"overall_status":"Recruiting","enrollment":" Enrollment 498","initiation":"Initiation: 04/19/2023","start_date":" 04/19/2023","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 10/30/2026","study_completion_date":" 10/30/2026","last_update_posted":"2025-02-12"},{"id":"a33d484d-46c6-4556-93ba-bc9cbf506681","acronym":"SAKK 19/17","url":"https://clinicaltrials.gov/study/NCT03620669","created_at":"2021-01-18T17:47:28.561Z","updated_at":"2025-02-25T15:17:49.744Z","phase":"Phase 2","brief_title":"1st Line Durvalumab in PS 2 NSCLC Patients","source_id_and_acronym":"NCT03620669 - SAKK 19/17","lead_sponsor":"Swiss Group for Clinical Cancer Research","biomarkers":" PD-L1 • ALK • ROS1","pipe":" | ","alterations":" PD-L1 expression • ALK rearrangement • ALK fusion","tags":["PD-L1 • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • ALK rearrangement • ALK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 12/04/2018","start_date":" 12/04/2018","primary_txt":" Primary completion: 01/19/2023","primary_completion_date":" 01/19/2023","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2025-02-12"},{"id":"63139aa8-19bf-4602-a810-5c7110a10962","acronym":"","url":"https://clinicaltrials.gov/study/NCT04423185","created_at":"2021-01-18T21:18:39.174Z","updated_at":"2025-02-25T15:26:22.079Z","phase":"Phase 2","brief_title":"PLATFORM Study of Precision Medicine for Rare Tumors","source_id_and_acronym":"NCT04423185","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" EGFR • HER-2 • BRAF • ALK • MET • BRCA1 • BRCA2 • KIT • ROS1 • CDKN2A","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • MET amplification • KIT mutation • ALK fusion • ROS1 fusion • CDKN2A mutation • MET mutation • BRAF amplification","tags":["EGFR • HER-2 • BRAF • ALK • MET • BRCA1 • BRCA2 • KIT • ROS1 • CDKN2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • MET amplification • KIT mutation • ALK fusion • ROS1 fusion • CDKN2A mutation • MET mutation • BRAF amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • imatinib • Tyvyt (sintilimab) • Alecensa (alectinib) • Zejula (niraparib) • Irene (pyrotinib) • Ameile (aumolertinib) • Vizimpro (dacomitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 770","initiation":"Initiation: 08/15/2020","start_date":" 08/15/2020","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2025-02-11"},{"id":"a0f41c59-aa55-45a8-ab7a-26f77921a6a6","acronym":"GO42286","url":"https://clinicaltrials.gov/study/NCT04774718","created_at":"2021-03-01T14:52:34.144Z","updated_at":"2025-02-25T16:45:19.897Z","phase":"Phase 1/2","brief_title":"A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors","source_id_and_acronym":"NCT04774718 - GO42286","lead_sponsor":"Hoffmann-La Roche","biomarkers":" ALK","pipe":" | ","alterations":" ALK fusion","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Alecensa (alectinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 09/14/2021","start_date":" 09/14/2021","primary_txt":" Primary completion: 02/28/2028","primary_completion_date":" 02/28/2028","study_txt":" Completion: 02/28/2032","study_completion_date":" 02/28/2032","last_update_posted":"2025-02-05"},{"id":"6da256ca-a5e6-48f5-9386-baa4180b20fa","acronym":"","url":"https://clinicaltrials.gov/study/NCT03420508","created_at":"2021-01-18T16:52:29.427Z","updated_at":"2025-02-25T16:52:07.457Z","phase":"Phase 2","brief_title":"Treating Patients With Melanoma and ALK Alterations With Ensartinib","source_id_and_acronym":"NCT03420508","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" BRAF • ALK","pipe":" | ","alterations":" BRAF V600 • ALK fusion • ALK mutation","tags":["BRAF • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600 • ALK fusion • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ensacove (ensartinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 01/10/2018","start_date":" 01/10/2018","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2025-02-04"},{"id":"d8999917-3c0d-4b22-aa4a-6a2e1a2de773","acronym":"TRITON","url":"https://clinicaltrials.gov/study/NCT06008093","created_at":"2023-08-23T15:11:10.888Z","updated_at":"2025-02-25T16:55:15.589Z","phase":"Phase 3","brief_title":"A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients","source_id_and_acronym":"NCT06008093 - TRITON","lead_sponsor":"AstraZeneca","biomarkers":" EGFR • KRAS • ALK • STK11 • KEAP1","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • STK11 mutation • ALK fusion • KEAP1 mutation","tags":["EGFR • KRAS • ALK • STK11 • KEAP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • STK11 mutation • ALK fusion • KEAP1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • pemetrexed"],"overall_status":"Recruiting","enrollment":" Enrollment 280","initiation":"Initiation: 04/04/2024","start_date":" 04/04/2024","primary_txt":" Primary completion: 08/17/2027","primary_completion_date":" 08/17/2027","study_txt":" Completion: 03/20/2031","study_completion_date":" 03/20/2031","last_update_posted":"2025-02-04"},{"id":"d19b5e70-e7cd-4b64-bac0-b73c5fbc1de7","acronym":"","url":"https://clinicaltrials.gov/study/NCT05236114","created_at":"2023-03-16T16:02:23.342Z","updated_at":"2025-02-25T15:00:16.802Z","phase":"","brief_title":"GEMINI-NSCLC: NSCLC Biomarker Study","source_id_and_acronym":"NCT05236114","lead_sponsor":"Tempus AI","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR mutation • ALK fusion","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK fusion"],"overall_status":"Recruiting","enrollment":" Enrollment 1200","initiation":"Initiation: 06/22/2022","start_date":" 06/22/2022","primary_txt":" Primary completion: 06/01/2029","primary_completion_date":" 06/01/2029","study_txt":" Completion: 06/01/2029","study_completion_date":" 06/01/2029","last_update_posted":"2024-12-16"},{"id":"cadb8f0d-9482-4575-b4e2-ae2b496d1ae5","acronym":"U31402-A-U102","url":"https://clinicaltrials.gov/study/NCT03260491","created_at":"2021-01-17T17:11:50.865Z","updated_at":"2025-02-25T16:06:47.472Z","phase":"Phase 1","brief_title":"U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT03260491 - U31402-A-U102","lead_sponsor":"Daiichi Sankyo","biomarkers":" ALK • ROS1","pipe":" | ","alterations":" EGFR L858R • EGFR exon 19 deletion • ALK fusion • EGFR L861Q • ROS1 fusion • EGFR G719X","tags":["ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR L858R • EGFR exon 19 deletion • ALK fusion • EGFR L861Q • ROS1 fusion • EGFR G719X"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e patritumab deruxtecan (U3-1402)"],"overall_status":"Recruiting","enrollment":" Enrollment 309","initiation":"Initiation: 10/30/2017","start_date":" 10/30/2017","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-11-22"},{"id":"d81d2aaa-ec8d-4ace-ab4c-6503e6ee6f96","acronym":"","url":"https://clinicaltrials.gov/study/NCT01725165","created_at":"2021-01-18T07:32:00.804Z","updated_at":"2025-02-25T16:30:21.179Z","phase":"Phase 2","brief_title":"Surgery and/or Radiation Therapy or Standard Therapy and/or Clinical Observation in Treating Patients With Previously Treated Stage IV Non-small Cell Lung Cancer","source_id_and_acronym":"NCT01725165","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" EGFR • ALK • EML4","pipe":" | ","alterations":" EGFR mutation • ALK fusion","tags":["EGFR • ALK • EML4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK fusion"],"overall_status":"Completed","enrollment":" Enrollment 85","initiation":"Initiation: 11/28/2012","start_date":" 11/28/2012","primary_txt":" Primary completion: 05/08/2024","primary_completion_date":" 05/08/2024","study_txt":" Completion: 05/08/2024","study_completion_date":" 05/08/2024","last_update_posted":"2024-10-24"},{"id":"7c4c2c5c-0d9e-41b0-96b2-8600aa7be62a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04318938","created_at":"2021-01-18T20:55:43.511Z","updated_at":"2025-02-25T14:51:44.818Z","phase":"Phase 2","brief_title":"Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping","source_id_and_acronym":"NCT04318938","lead_sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","biomarkers":" ALK • TP53","pipe":" | ","alterations":" TP53 mutation • ALK positive • ALK rearrangement • ALK fusion • ALK mutation","tags":["ALK • TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • ALK positive • ALK rearrangement • ALK fusion • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Alunbrig (brigatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 118","initiation":"Initiation: 03/30/2020","start_date":" 03/30/2020","primary_txt":" Primary completion: 01/16/2026","primary_completion_date":" 01/16/2026","study_txt":" Completion: 01/16/2026","study_completion_date":" 01/16/2026","last_update_posted":"2024-10-14"},{"id":"23fc48e8-8769-4759-8eb9-b726dad67c99","acronym":"Lung-MAP Non-Matched Sub-Study","url":"https://clinicaltrials.gov/study/NCT03971474","created_at":"2021-01-18T19:32:15.856Z","updated_at":"2024-07-02T16:34:25.767Z","phase":"Phase 2","brief_title":"Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)","source_id_and_acronym":"NCT03971474 - Lung-MAP Non-Matched Sub-Study","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" EGFR • BRAF • ALK • ROS1","pipe":" | ","alterations":" BRAF V600E • EGFR mutation • BRAF V600 • EGFR T790M • ALK fusion • ROS1 fusion","tags":["EGFR • BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • EGFR mutation • BRAF V600 • EGFR T790M • ALK fusion • ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • gemcitabine • docetaxel • Cyramza (ramucirumab) • pemetrexed • lexatumumab (ETR2-ST01)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 166","initiation":"Initiation: 05/28/2019","start_date":" 05/28/2019","primary_txt":" Primary completion: 04/14/2022","primary_completion_date":" 04/14/2022","study_txt":" Completion: 07/15/2024","study_completion_date":" 07/15/2024","last_update_posted":"2024-06-14"},{"id":"351db7f3-6d9a-4613-9f48-4b25eb1e0b71","acronym":"","url":"https://clinicaltrials.gov/study/NCT03894618","created_at":"2021-01-18T19:11:01.852Z","updated_at":"2024-07-02T16:34:26.954Z","phase":"Phase 1","brief_title":"SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas","source_id_and_acronym":"NCT03894618","lead_sponsor":"Shattuck Labs, Inc.","biomarkers":" EGFR • ALK • MSI","pipe":" | ","alterations":" EGFR mutation • MSI-H/dMMR • ALK fusion","tags":["EGFR • ALK • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • MSI-H/dMMR • ALK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SL-279252"],"overall_status":"Completed","enrollment":" Enrollment 49","initiation":"Initiation: 03/26/2019","start_date":" 03/26/2019","primary_txt":" Primary completion: 05/04/2023","primary_completion_date":" 05/04/2023","study_txt":" Completion: 05/04/2023","study_completion_date":" 05/04/2023","last_update_posted":"2024-06-12"},{"id":"c473d3f8-3616-45e8-a118-51ded41b67b6","acronym":"POSEIDON","url":"https://clinicaltrials.gov/study/NCT03164616","created_at":"2021-01-18T15:36:07.820Z","updated_at":"2024-07-02T16:34:26.781Z","phase":"Phase 3","brief_title":"Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).","source_id_and_acronym":"NCT03164616 - POSEIDON","lead_sponsor":"AstraZeneca","biomarkers":" EGFR • PD-L1 • ALK","pipe":" | ","alterations":" EGFR mutation • ALK fusion","tags":["EGFR • PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • Imfinzi (durvalumab) • gemcitabine • albumin-bound paclitaxel • Imjudo (tremelimumab-actl) • pemetrexed"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1186","initiation":"Initiation: 06/01/2017","start_date":" 06/01/2017","primary_txt":" Primary completion: 03/12/2021","primary_completion_date":" 03/12/2021","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-06-12"},{"id":"242a00a6-2e7d-4b18-8a4a-57905c77b105","acronym":"Lung-MAP Sub-Study","url":"https://clinicaltrials.gov/study/NCT05364645","created_at":"2022-05-06T18:55:15.353Z","updated_at":"2024-07-02T16:34:27.438Z","phase":"Phase 2","brief_title":"Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer","source_id_and_acronym":"NCT05364645 - Lung-MAP Sub-Study","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" EGFR • KRAS • BRAF • ALK • MET • RET • ROS1","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • EGFR T790M • RET fusion • MET exon 14 mutation • ALK fusion • ROS1 fusion • MET mutation • RET positive","tags":["EGFR • KRAS • BRAF • ALK • MET • RET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • EGFR T790M • RET fusion • MET exon 14 mutation • ALK fusion • ROS1 fusion • MET mutation • RET positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Retevmo (selpercatinib) • pemetrexed • Pemfexy (pemetrexed)"],"overall_status":"Recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 07/25/2022","start_date":" 07/25/2022","primary_txt":" Primary completion: 06/27/2023","primary_completion_date":" 06/27/2023","study_txt":" Completion: 05/01/2029","study_completion_date":" 05/01/2029","last_update_posted":"2024-06-11"},{"id":"b148efd6-3461-4443-b111-648b5d1400c0","acronym":"ECOG-ACRIN LUNG-MAP SUB-STUDY","url":"https://clinicaltrials.gov/study/NCT04625647","created_at":"2021-01-19T20:35:28.296Z","updated_at":"2024-07-02T16:34:27.131Z","phase":"Phase 2","brief_title":"Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)","source_id_and_acronym":"NCT04625647 - ECOG-ACRIN LUNG-MAP SUB-STUDY","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" EGFR • KRAS • BRAF • ALK • ROS1","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • EGFR mutation • KRAS G12C • BRAF V600 • EGFR T790M • ALK fusion • ROS1 fusion • KRAS G12","tags":["EGFR • KRAS • BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • EGFR mutation • KRAS G12C • BRAF V600 • EGFR T790M • ALK fusion • ROS1 fusion • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Lumakras (sotorasib)"],"overall_status":"Recruiting","enrollment":" Enrollment 116","initiation":"Initiation: 04/16/2021","start_date":" 04/16/2021","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2024-06-11"},{"id":"543cd16b-633b-4c4e-b967-73fb1131c4b4","acronym":"LUNG-MAP Sub-Study","url":"https://clinicaltrials.gov/study/NCT03845296","created_at":"2021-01-17T17:13:03.964Z","updated_at":"2024-07-02T16:34:59.337Z","phase":"Phase 2","brief_title":"Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)","source_id_and_acronym":"NCT03845296 - LUNG-MAP Sub-Study","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" EGFR • BRAF • ALK • BRCA1 • BRCA2 • ROS1 • HRD • BRCA • CD4","pipe":" | ","alterations":" BRAF V600E • BRCA2 mutation • BRCA1 mutation • EGFR mutation • BRAF V600 • EGFR T790M • HRD • ALK fusion • ROS1 fusion • HRD + BRCA1 mutation","tags":["EGFR • BRAF • ALK • BRCA1 • BRCA2 • ROS1 • HRD • BRCA • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRCA2 mutation • BRCA1 mutation • EGFR mutation • BRAF V600 • EGFR T790M • HRD • ALK fusion • ROS1 fusion • HRD + BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rubraca (rucaparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 04/16/2019","start_date":" 04/16/2019","primary_txt":" Primary completion: 01/01/2022","primary_completion_date":" 01/01/2022","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-06-04"},{"id":"8a3d3d41-a452-48ff-8178-8d754ba2fbf3","acronym":"","url":"https://clinicaltrials.gov/study/NCT05170204","created_at":"2021-12-27T15:54:25.891Z","updated_at":"2024-07-02T16:34:59.196Z","phase":"Phase 3","brief_title":"A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT05170204","lead_sponsor":"Hoffmann-La Roche","biomarkers":" PD-L1 • RET • ROS1","pipe":" | ","alterations":" RET fusion • ALK fusion • ROS1 fusion","tags":["PD-L1 • RET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion • ALK fusion • ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Rozlytrek (entrectinib) • Alecensa (alectinib) • Gavreto (pralsetinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 121","initiation":"Initiation: 11/01/2022","start_date":" 11/01/2022","primary_txt":" Primary completion: 06/17/2029","primary_completion_date":" 06/17/2029","study_txt":" Completion: 04/14/2035","study_completion_date":" 04/14/2035","last_update_posted":"2024-06-04"},{"id":"ba697a0c-0213-4400-8a69-554239875d35","acronym":"LUNG-MAP Sub-Study","url":"https://clinicaltrials.gov/study/NCT04268550","created_at":"2021-01-18T14:26:41.644Z","updated_at":"2024-07-02T16:34:59.356Z","phase":"Phase 2","brief_title":"Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)","source_id_and_acronym":"NCT04268550 - LUNG-MAP Sub-Study","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" EGFR • KRAS • BRAF • ALK • MET • RET • ROS1","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • EGFR T790M • RET fusion • MET exon 14 mutation • ALK fusion • ROS1 fusion • MET mutation • RET positive","tags":["EGFR • KRAS • BRAF • ALK • MET • RET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • EGFR T790M • RET fusion • MET exon 14 mutation • ALK fusion • ROS1 fusion • MET mutation • RET positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Retevmo (selpercatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 124","initiation":"Initiation: 04/08/2020","start_date":" 04/08/2020","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-06-04"}]